Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin for NAFLD in Type 2 Diabetes
NCT02263677Phase 4Withdrawn
- Sponsor
- University of Missouri
- Start
- Mar 2014
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sitagliptin in non-alcoholic fatty liver disease (NAFLD), sponsored by University of Missouri. Primary endpoint: Change in Liver steatosis at 6 months. Planned start Mar 2014; status: withdrawn.
02
Drugs
sitagliptin
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT02263677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02263677.